Search results
Results from the WOW.Com Content Network
On 20 April 2018, a laboratory accident led to a single worker being exposed to the Ebola virus, though he did not develop symptoms. [99] [100] 2022 DRC: EBOV 5 5 An outbreak in DRC began on April 23, and has killed 100% of those infected. [101] 2022 DRC: EBOV 1 1 A single case was confirmed in North Kivu. [102] 2025 Uganda: SUDV 9 1
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. [1] Symptoms typically start anywhere between two days and three weeks after infection. [3] The first symptoms are usually fever, sore throat, muscle pain, and headaches. [1]
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication used for the treatment of Zaire ebolavirus (Ebolavirus) infection. [2] [3]The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.
Among patients treated with it, 34% died; the mortality rate improved if the drug was administered soon after infection, in a timely diagnosis – critical for those infected with diseases like Ebola that can cause sepsis and, eventually, multiple organ dysfunction syndrome, more quickly than other diseases. [22]
LONDON (Reuters) -Obesity drugs will not join the World Health Organization's (WHO) latest essential medicines list, but treatments for diseases, including Ebola and multiple sclerosis will ...
The drug is composed of three monoclonal antibodies (mAbs), initially harvested from mice exposed to Ebola virus proteins, that have been chimerized with human constant regions. [6] The components are chimeric monoclonal antibody c13C6 from a previously existing antibody cocktail called "MB-003" and two chimeric mAbs from a different antibody ...
[43] [44] A phase one trial May 2010, to November 2011, showed that the drug was safe in healthy adults; [45] [46] however, a later phase one trial was withdrawn due to funding constraints. [47] JK-05 is an antiviral drug developed by Sihuan Pharmaceutical along with Academy of Military Medical Sciences. In tests on mice, JK-05 shows efficacy ...
cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID). [1]